Early treatment for eosinophilic esophagitis may lower children's asthma risk
Young children treated for eosinophilic esophagitis (EoE) with dupilumab were less likely to develop asthma in the future compared with children who received a different treatment. The findings come from a new study presented at the American College of Allergy, Asthma and Immunology (ACAAI) 2026 Annual Scientific Meeting. The study also appears in Annals of Allergy Asthma & Immunology.
Read original article on Medical Xpress - latest medical and health news stories →Related news
-
Head-to-head trial reveals better immune-dampening drug for psoriatic arthritis
United Kingdom
-
Unusual pathogen: Fatal viral infection identified during advanced cancer immunotherapy
United Kingdom
-
Clinicians know food allergy panels can lead to overdiagnosis—but order them anyway
United Kingdom
-
Language barriers may keep families from introducing peanuts early
United Kingdom
-
School nurses find stock epinephrine improves safety of students with severe allergies
United Kingdom
-
Wildfire smoke during pregnancy linked to asthma in young children
United Kingdom
-
Patients with meat allergy who take omalizumab may see improvement of symptoms
United Kingdom
-
Small RNA from surrounding cells promotes triple-negative breast cancer growth
United Kingdom